Holen Sie sich die Stockscreener-App
68.01
9.94%
-7.51
Schlusskurs vom Vortag:
$75.52
Offen:
$70.92
24-Stunden-Volumen:
4.33M
Relative Volume:
2.43
Marktkapitalisierung:
$5.64B
Einnahmen:
$1.73B
Nettoeinkommen (Verlust:
$682.64M
KGV:
8.7909
EPS:
7.7364
Netto-Cashflow:
$411.18M
1W Leistung:
-11.47%
1M Leistung:
-16.62%
6M Leistung:
-9.96%
1J Leistung:
+30.51%
1-Tages-Spanne:
$64.57
$73.72
1-Wochen-Bereich:
$64.57
$79.33
52-Wochen-Spanne:
$43.17
$90.87
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
68.01 | 6.29B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-12-01 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
PTC Therapeutics (PTCT) Receives a Hold from RBC Capital - The Globe and Mail
PTCT|PTC Therapeutics Inc|Price:75.790|Chg%:-1.030 - TradingKey
PTC Therapeutics Inc (PTCT) Balance Sheet - TradingKey
PTC Therapeutics' Phenylketonuria Physician Survey Yielded Mixed Results on Sephience Launch Momentum, RBC Says - Moomoo
PTC Therapeutics Inc (PTCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PTC Therapeutics Inc (PTCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PTC Therapeutics Inc (PTCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PTC Therapeutics Inc (PTCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PTC Therapeutics to Participate at Upcoming Investor Conferences - GuruFocus
PTC Therapeutics Inc (PTCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PTC Therapeutics, Inc. Revenue Breakdown – BOATS:PTCT - TradingView
PTC Therapeutics Inc (PTCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PTCT|PTC Therapeutics Inc|Price:76.820|Chg%:-1.630 - TradingKey
PTC Therapeutics Inc (PTCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PTCT5396017 Bond Profile — Key Metrics - TradingView
Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Barclays Remains a Buy on PTC Therapeutics (PTCT) - The Globe and Mail
Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $120 - Moomoo
Responsive Playbooks and the PTCT Inflection - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
PTCT Maintained by Wells Fargo -- Price Target Lowered to $93.00 - GuruFocus
Is PTC Therapeutics (PTCT) Cheap On Fast Track News For PTC518? - Sahm
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix - TradingView
Reasons why investors should consider betting on PTC stock now - MSN
PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026 - Sahm
Form 4 PTC Therapeutics Inc For: 16 July By Investing.com - Investing.com Nigeria
PTC Therapeutics CFO Pierre Gravier sells $280,742 in shares By Investing.com - Investing.com South Africa
PTC Therapeutics schedules second-quarter 2026 results webcast conference call - Bitget
PTC Therapeutics CFO Pierre Gravier sells $280,742 in shares - Investing.com
PTC Therapeutics (PTCT) CFO auto-sells 3,494 shares to cover RSU taxes - Stock Titan
PTCT Maintained by Cantor FitzgeraldPrice Target Raised to $1 - GuruFocus
Cantor Fitzgerald raises PTC Therapeutics stock price target on Sephience outlook - Investing.com Canada
PTC Therapeutics Sets July 30 Webcast for Business Update - Stock Titan
Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $130 - Moomoo
PTC Therapeutics (PTCT) Gets a Buy from Bank of America Securities - The Globe and Mail
Cantor Fitzgerald reiterates Overweight on PTC Therapeutics stock By Investing.com - Investing.com Canada
What PTC Therapeutics (PTCT)'s Q1 Beat and Sephience Outlook Shift Mean For Shareholders - Sahm
Form 144 PTC THERAPEUTICS For: 14 July By Investing.com - Investing.com Nigeria
PTC THERAPEUTICS, INC. SEC Filing (Jul 14, 2026) - Stock Titan
PTC Therapeutics (PTCT) Q1 2025 earnings summary - Quartr
PTC Therapeutics (PTCT) 2024 Wells Fargo Healthcare Conference Summary - Quartr
Form 4 PTC Therapeutics Inc For: 13 July By Investing.com - Investing.com South Africa
PTC Therapeutics chief technical ops officer sells $222,376 in shares - Investing.com UK
Mary L. Smith, director at PTC Therapeutics, sells $1.43m in stock - Investing.com UK
PTC Therapeutics chief technical ops officer sells $222,376 in shares By Investing.com - Investing.com Nigeria
What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million - The Motley Fool
What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million - The Motley Fool
Mary L. Smith, director at PTC Therapeutics, sells $1.43m in stock By Investing.com - Investing.com South Africa
PTC Therapeutics (PTCT) director trades 15,834 shares via option exercise and sale - Stock Titan
J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $91 - Moomoo
PTC Therapeutics (PTCT) On Russell Index Inclusion And Pipeline Optimism With Fair Value In Focus - simplywall.st
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):